The therapeutic potential of angiotensin-converting enzyme inhibitor enalapril to ameliorate muscle atrophy in a murine model

Authors

  • Sima Seifi Metabolic Disorders Research Center, Department of Biochemistry and Biophysics, Golestan University of Medical Sciences Gorgan, Golestan Province, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0002-8115-2430
  • Seyedeh Elnaz Nazari Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0003-4471-0162
  • Amir Avan Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0002-4968-0962
  • Nima Khalili-Tanha Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0001-5477-8369
  • Fereshteh Asgharzadeh Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0002-8349-3722
  • Fatemeh Babaei Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0001-9398-5555
  • Ghazaleh Khalili-Tanha Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0001-5824-1390
  • Seyyedeh Zahra Asghari Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0002-1855-9713
  • Mahdieh Darroudi Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran https://orcid.org/0000-0002-9152-2642
  • Gordon A. Ferns Brighton & Sussex Medical School, Department of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK https://orcid.org/0000-0002-0957-8349
  • Abdoljalal Marjani Metabolic Disorders Research Center, Department of Biochemistry and Biophysics, Golestan University of Medical Sciences Gorgan, Golestan Province, Iran; E-mail: marjani@goums.ac.ir https://orcid.org/0000-0003-2826-5951
  • Majid Khazaei Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, Tel: +98 513 8002298; E-mail: Khazaeim@mums.ac.ir https://orcid.org/0000-0002-7979-5699

DOI:

https://doi.org/10.17179/excli2023-6822

Keywords:

muscle atrophy, limb immobilization, oxidative stress, enalapril, inflammation, renin-angiotensin system

Abstract

Muscle atrophy due to limb immobilization and inactivity is a common consequence of many diseases and treatment processes. One of the systems activated in inflammatory conditions is the renin-angiotensin system (RAS). The present study was conducted with the aim of investigating the effects of one of the angiotensin-converting enzyme (ACE) inhibitors, enalapril, on improving muscle atrophy caused by immobility. The study was conducted in three groups: a control, an atrophy, and an atrophy group treated with enalapril on Balb/c mice. After tying a splint to cause atrophy in one of the legs, daily treatment with enalapril intraperitoneally (dissolved in DMSO) at a dose of 10 mg/kg/day was done for 7 days. On the eighth day, the splint was opened and half of the mice were evaluated. Then, in the recovery phase, treatment with enalapril was continued in the remaining mice for 10 days without a splint. At the end of each phase, the mice were examined for the muscle strength of the lower limb muscles, and histological and biochemical analyses were subsequently carried out. The tissue level of the oxidative stress index MDA was evaluated, which showed a significantly lower level in the enalapril group compared to the atrophy group (*P<0.1). Also, inflammatory factors in the enalapril group showed a decrease compared to the atrophy group. The strength of four limbs in the mice of the treatment group (-18.36 ± 1.70 %) was significantly higher than that of the atrophy group (-30.33 ± 3 %) at the end of the atrophy phase and also after 10 days of recovery. The results suggest that the use of enalapril that reduces the activation of angiotensin II-dependent pro-oxidant and pro-inflammatory pathways may improve the functional disorder and muscle necrosis in the murine model of muscle atrophy.

Author Biography

Seyyedeh Zahra Asghari, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

neue Email-Adresse eingegeben nach Veröffentlichung, 25.04.2024

Additional Files

Published

2024-04-25

How to Cite

Seifi, S., Nazari, S. E., Avan, A., Khalili-Tanha, N., Asgharzadeh, F., Babaei, F., … Khazaei, M. (2024). The therapeutic potential of angiotensin-converting enzyme inhibitor enalapril to ameliorate muscle atrophy in a murine model. EXCLI Journal, 23, 600–611. https://doi.org/10.17179/excli2023-6822

Issue

Section

Original articles

Categories

Most read articles by the same author(s)